Finance5 sources
Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion
- Eli Lilly plans to buy Calytrix Bio for up to $1.5 billion.
- The acquisition aims to bolster Eli Lilly's cancer and immunology business.
- This deal is part of Eli Lilly's broader $32 billion acquisition spree in 2026.
- Calytrix Bio specializes in developing treatments for rare blood cancers.
- The acquisition is expected to enhance Eli Lilly's market position in oncology.
Timeline
Lilly to buy Calytrix for up to $1.5 billion
Eli Lilly agrees to buy Calytrix Bio for up to $1.5 billion.
Lilly signs cancer research deal with Stipple Bio
Lilly signs a cancer research deal with Stipple Bio worth up to $5.9 billion.
Lilly Buying Spree Surpasses $32B
Lilly's acquisition of Calytrix Bio is part of a $32 billion wave of acquisitions in 2026.
Latest
Lilly's Next Big Growth Opportunity
Lilly's third-quarter update shows core growth drivers, including Mounjaro and Zepbound.
Articles (8)
The Motley Fool·
Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain Sight
Yahoo Finance·
Eli Lilly (LLY) – The Only Healthcare Name in Ken Fisher’s Fastest-Growing Top Positions
Bloomberg·
Lilly Buying Spree Surpasses $32B
The Wall Street Journal·
Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion
Reuters·
Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion
Bloomberg·
Eli Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion
Bloomberg·
Lilly Pushes Buying Spree Beyond $32B With Calytrix Deal
Reuters·
Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet